10x Genomics (TXG)
(Delayed Data from NSDQ)
$27.59 USD
+0.69 (2.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.92 +0.33 (1.20%) 5:08 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.59 USD
+0.69 (2.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.92 +0.33 (1.20%) 5:08 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
Zacks News
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Down -23.92% in 4 Weeks, Here's Why 10x Genomics (TXG) Looks Ripe for a Turnaround
by Zacks Equity Research
10x Genomics (TXG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -13.89% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 260% and 2.41%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
iRhythm Technologies (IRTC) Moves 7.4% Higher: Will This Strength Last?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -35.90% and 5.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -15.79% and 4.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NextGen (NXGN) Riding on the Success of Cloud-Based Solution
by Zacks Equity Research
NextGen's (NXGN) cloud-based healthcare technology solutions boost the company's prospect. Strong adoption of its services continues to boost revenues.
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 48.28% and 6.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Syneos Health (SYNH) Q4 Earnings Expected to Decline
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Info Systems Stocks Braving Industry-wide Headwinds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like 10x Genomics (TXG), NextGen Healthcare (NXGN) and Health Catalyst (HCAT) are expected to gain as COVID-19 severity fades.
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 17.78% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Rising Visits Help Teladoc (TDOC) Beat on Earnings in Q3?
by Zacks Equity Research
The third-quarter results of Teladoc (TDOC) are likely to reflect a rise in Access Fees and Visit Fee revenues.
PacBio's (PACB) Latest Offering to Enhance Disease Discoveries
by Zacks Equity Research
PacBio's (PACB) latest sequencing kit is expected to help generate insights into how single-cell research can power new disease discoveries and the identification of therapeutic targets across many categories.
Inspire (INSP) Stock Jumps 5.6%: Will It Continue to Soar?
by Zacks Equity Research
Inspire (INSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
American Well Corporation (AMWL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
American Well Corporation (AMWL) delivered earnings and revenue surprises of 0% and 3.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?